Thursday, October 12, 2017

Copanlisib Tested in Relapsed/ Refractory Indolent Lymphoma (CME/CE)

(MedPage Today) -- Upregulated PI3K/BCR signaling associated with better outcomes in phase II study

No comments:

Post a Comment